IMIDomics, Inc. is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs).
In the fifteen years since it began, the IMID-Biobank has grown to include real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications: rheumatoid arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and systemic lupus erythematosus. IMIDomics maintains an exclusive commercial license to use this leading resource on IMIDs for treatment discovery and development. IMIDomics utilizes a proprietary digital bioinformatics portal that integrates and interrogates data to generate novel insights into disease mechanisms, including identification of potential new drug targets. This integrated capability, called the IMIDomics Precision Discovery Platform, enables precision medicine for IMID patients and will lead to therapies that address needs not addressed by current medicines.